MICB and cancer: Therefore, an antibody targeting MICA α3 was synthesized to prevent the proteolysis of MICA and MICB from cancer cells, thus allowing the binding of NK cell activating receptor, NKG2D with MICA/B to activate cytotoxic NK cells (115).